ADHD Portfolio (e.g., Karbinal™ ER)
Attention-Deficit/Hyperactivity Disorder (ADHD)
CommercialMarketed
Key Facts
Indication
Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase
Commercial
Status
Marketed
Company
About Aytu BioPharma
Aytu BioPharma is a publicly traded, commercial-stage company with a mission to become a leading CNS-focused specialty pharma by commercializing novel therapeutics and ensuring broad patient access. Its core strategy leverages a dual-portfolio approach: a high-growth CNS franchise anchored by the recently launched EXXUA™ for MDD and an ADHD portfolio, alongside a legacy non-CNS business that provides stable cash flow. The company differentiates itself through its integrated commercial engine, particularly the Aytu RxConnect patient support program, aiming to overcome market access barriers in complex CNS markets.
View full company profileTherapeutic Areas
Other Attention-Deficit/Hyperactivity Disorder (ADHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mazindol ER (NLS-4) | NLS Pharmaceutics | Phase 2 |
| CTx-1301 | Cingulate Therapeutics | Phase 3 |
| CTx-1302 | Cingulate Therapeutics | Phase 3 |
| Botanically-derived Compound(s) | ABVC BioPharma | Phase II |